Accessibility Menu
BioSyent logo

BioSyent(TSXV) RX

Market CapCA$180.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1988)+1,429%
5 Year+121%
1 Year+35%
1 Month+9%
CA$15.88
-0.75%
-0.12Today
BioSyent last closing stock price
MetricPriceDate
Last closeCAD 16.002026-09-02
BioSyent stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.36%CAD 15.782026-08-26
1 month+8.85%CAD 14.702026-07-31
3 month+14.69%CAD 13.952026-06-04
Year to date+27.08%CAD 12.592025-12-31
1 year+35.37%CAD 11.822025-09-02
3 year+107.88%CAD 7.702023-09-01
5 year+120.57%CAD 7.252021-09-03
Since inception+1,429.31%CAD 1.051988-09-12

BioSyent Financials at a Glance

Market Cap

CA$180.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$55.67M

Net Income (TTM)

CA$9.87M

EPS (TTM)

CA$0.86

P/E Ratio

18.35

Dividend

CA$0.22

Beta (Volatility)

0.03 (Low)

Price

CA$15.88

Volume

2,406

Open

CA$16.04

Previous Close

CA$15.88

Daily Range

CA$15.88 - CA$16.04

52-Week Range

CA$10.65 - CA$16.25

Estimated Earnings Date

Nov 19, 2026

RX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioSyent

BioSyent Inc. is a Canadian pharmaceutical company that specializes in acquiring, developing, and selling healthcare products both domestically and internationally. The company focuses on innovative solutions for various medical needs, particularly in the areas of iron deficiency anemia and women's health.

Products and Services
  • FeraMAX products for iron deficiency anemia treatment and prevention
  • Tibella, a hormone replacement therapy for menopausal symptoms
  • Inofolic, a natural health product for polycystic ovarian syndrome
Growth Outlook
  • Recent quarterly revenue reached CAD 19.87 million, a significant increase
  • Trailing twelve months (TTM) revenue shows a strong upward trend
  • Expansion into international markets is expected to drive future growth
Financial Highlights
  • Net income for the latest quarter was CAD 2.85 million, reflecting strong profitability
  • TTM gross profit margin stands at 70.2%, indicating efficient operations
  • Current ratio of 2.07 suggests strong liquidity and financial health
BioSyent Inc. has established itself as a key player in the pharmaceutical industry, focusing on innovative healthcare solutions. The company's diverse product portfolio addresses critical health issues, particularly in iron deficiency and women's health. Recent financial performance indicates robust growth, with a notable increase in quarterly revenue and net income. The strong gross profit margin and healthy liquidity position further enhance the company's appeal to potential investors. With plans for international expansion, BioSyent Inc. is well-positioned for continued growth in the evolving healthcare landscape.
AI Generated • Aug 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

61

CEO

René C. Goehrum

Website

www.biosyent.com

Headquarters

Mississauga, ON L5N 6M1, CA

RX Financials

Key Financial Metrics (TTM)

Gross Margin

70.21%

Operating Margin

23.21%

Net Income Margin

17.73%

Return on Equity

22.92%

Return on Capital

26.74%

Return on Assets

16.32%

Earnings Yield

5.45%

Dividend Yield

1.34%

Payout Ratio

24.01%

Stock Overview

Market Cap

CA$180.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.31M

Volume

2.41K

Avg. Volume

11.61K

Financials (TTM)

Gross Profit

CA$39.09M

Operating Income

CA$12.92M

EBITDA

CA$15.12M

Operating Cash Flow

CA$12.09M

Capital Expenditure

-CA$298.65K

Free Cash Flow

CA$11.80M

Cash & ST Invst.

CA$8.94M

Total Debt

CA$3.14M

BioSyent Performance Analysis

BioSyent annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 27,925,187-2.4%
20232023-12-31CAD 31,590,30213.1%
20242024-12-31CAD 35,030,89710.9%
20252025-12-31CAD 43,051,98322.9%
BioSyent sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3020.1%
Q42025-12-31-20.9%
Q12026-03-3143.8%
Q22026-06-3042.9%
BioSyent annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD 0.44-10.8%
20232023-12-31CAD 0.5322.0%
20242024-12-31CAD 0.6216.0%
20252025-12-31CAD 0.7827.2%
BioSyent sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3027.8%
Q42025-12-31-21.7%
Q12026-03-3111.1%
Q22026-06-3025.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$19.87M

+95.2%

Gross Profit

CA$12.92M

+63.3%

Gross Margin

65.02%

N/A

Market Cap

CA$180.94MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$3.02M

N/A

Employees

60

N/A

Net Income

CA$2.85M

+41.2%

EBITDA

CA$4.98M

+67.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$8.94M

-56.1%

Total Debt

CA$3.14M

+233.3%

Accounts Receivable

CA$6.77M

+37.5%

Inventory

CA$10.74M

+121.0%

Long Term Debt

CA$698.77K

-4.9%

Short Term Debt

CA$2.44M

+1079.2%

Return on Assets

16.32%

N/A

Return on Invested Capital

27.70%

N/A

Free Cash Flow

CA$2.54M

-26.0%

Operating Cash Flow

CA$2.55M

-26.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LOVE.VCannara Biotech Inc.
CA$1.89+6.18%
MDP.TOMedexus Pharmaceuticals Inc.
CA$5.10-2.49%
ZEN.VZentek Ltd.
CA$0.72+2.86%
DB.VDecibel Cannabis Company Inc.
CA$1.81-2.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.77-0.01%
HPEHewlett Packard Enterprise
$54.44+0.05%
FFord Motor Company
$14.41+0.02%
SNAPSnap
$5.70+0.02%

Questions About RX

What is the current price of BioSyent?

BioSyent is trading at CA$15.88 per share.

What is the 52-week range for BioSyent?

Over the past 52 weeks, BioSyent has traded between CA$10.65 and CA$16.25.

How much debt does BioSyent have?

As of the most recent reporting period, BioSyent reported total debt of CA$3.14M.

How much cash does BioSyent have on hand?

BioSyent reported CA$5.18M in cash and cash equivalents in its most recent financial results.

What is BioSyent’s dividend yield?

BioSyent currently has a dividend yield of 1.34%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services